Cycle Pharmaceuticals Hauls In USD 25 Million In A Debt Financing Agreement
Cycle Pharmaceuticals, a biotech company focusing exclusively on rare diseases, announced a strategic financing agreement worth USD25 million credit facility with Deutsche Bank AG.
Headquartered in the UK, Cycle Pharmaceuticals provides drug treatments and services that revolve around rare genetic neurological and metabolic disorders. This strategic partnership enables Cycle to build on the success of NITYR (nitisinone) Tablets. The U.S. FDA approves NITYR for the treatment of Hereditary Tyrosinemia type 1 (HT-1) combined with dietary restriction of tyrosine and phenylalanine...
